We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.615 | 0.15% | 402.755 | 402.67 | 402.87 | 404.00 | 398.46 | 402.95 | 387,768 | 16:41:21 |
From May 2022 to May 2024
By Colin Kellaher
Shares of Catalyst Biosciences Inc. more than doubled in early trading Monday after the biopharmaceutical company said it sold its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Inc. for $60 million in cash.
The South San Francisco, Calif., company in February said it planned to explore options to monetize its assets, and it hired investment bank Perella Weinberg Partners to assist with the process.
Catalyst said it has significantly reduced its cash burn, and that it continues to work with its advisers to evaluate additional moves.
The company said its product candidates now consist of the coagulation-related assets marzeptacog alfa (activated), dalcinonacog alfa and CB 2679d-GT.
Catalyst shares, which closed Friday at 38 cents, were recently changing hands at 92 cents.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 23, 2022 09:53 ET (13:53 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
